Consumer Defensive - Household & Personal Products - NYSE - US
$ 23.82
0.889 %
$ 45.7 B
Market Cap
43.31
P/E
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.[ Read More ]
The intrinsic value of one KVUE stock under the base case scenario is HIDDEN Compared to the current market price of 23.8 USD, Kenvue Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart KVUE
FINANCIALS
15.4 B
REVENUE
2.51 B
OPERATING INCOME
1.66 B
NET INCOME
3.17 B
OPERATING CASH FLOW
-488 M
INVESTING CASH FLOW
-2.53 B
FINANCING CASH FLOW
3.9 B
REVENUE
654 M
OPERATING INCOME
383 M
NET INCOME
249 M
OPERATING CASH FLOW
-56 M
INVESTING CASH FLOW
-162 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Kenvue Inc.
| Current Assets | 6.14 B |
| Cash & Short-Term Investments | 1.38 B |
| Receivables | 2.07 B |
| Other Current Assets | 2.68 B |
| Non-Current Assets | 21.7 B |
| Long-Term Investments | 71 M |
| PP&E | 2.18 B |
| Other Non-Current Assets | 19.5 B |
| Current Liabilities | 5.48 B |
| Accounts Payable | 2.49 B |
| Short-Term Debt | 643 M |
| Other Current Liabilities | 2.35 B |
| Non-Current Liabilities | 11.2 B |
| Long-Term Debt | 7.78 B |
| Other Non-Current Liabilities | 3.38 B |
EFFICIENCY
Earnings Waterfall
Kenvue Inc.
| Revenue | 15.4 B |
| Cost Of Revenue | 6.83 B |
| Gross Profit | 8.61 B |
| Operating Expenses | 6.13 B |
| Operating Income | 2.51 B |
| Other Expenses | 848 M |
| Net Income | 1.66 B |
RATIOS
55.77%
GROSS MARGIN
16.27%
OPERATING MARGIN
10.78%
NET MARGIN
14.84%
ROE
5.97%
ROA
9.79%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Kenvue Inc.
| Net Income | 1.66 B |
| Depreciation & Amortization | 627 M |
| Capital Expenditures | -469 M |
| Stock-Based Compensation | 188 M |
| Change in Working Capital | 797 M |
| Others | 20 M |
| Free Cash Flow | 2.7 B |
Wall Street Analysts Price Targets
Kenvue Inc.
Wall Street analysts predict an average 1-year price target for KVUE of $22.6 , with forecasts ranging from a low of $18 to a high of $27 .
KVUE Lowest Price Target
Wall Street Target
18 USD
-24.43%
KVUE Average Price Target
Wall Street Target
22.6 USD
-5.24%
KVUE Highest Price Target
Wall Street Target
27 USD
13.35%
4. DIVIDEND ANALYSIS
0.89%
DIVIDEND YIELD
0.205 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Kenvue Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Aug 30, 2023
|
Bought 129 K USD
|
ALLISON RICHARD E JR
Director |
+ 5598
|
22.9589 USD |
|
1 year ago
May 11, 2023
|
Bought 525 K USD
|
ALLISON RICHARD E JR
Director |
+ 20000
|
26.2616 USD |
7. News
Tylenol maker Kenvue hails efficiency gains as activist Starboard watches on
Kenvue Inc (NYSE:KVUE), the maker of Listerine, Tylenol, Aveeno and Band-Aid, reported slightly lower sales than expected but earnings were just above Wall Street estimates. The company has been in a more intense spotlight coming into these results after reports emerged that activist investor Starboard Value has taken a stake and is eyeing changes.
proactiveinvestors.com
- 1 week ago
Kenvue, Inc. (KVUE) Q3 2024 Earnings Call Transcript
Kenvue, Inc. (NYSE:KVUE ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Sofya Tsinis - Head, IR Thibaut Mongon - CEO Paul Ruh - CFO Conference Call Participants Bonnie Herzog - Goldman Sachs Anna Lizzul - Bank of America Andrea Teixeira - J.P. Morgan Peter Grom - UBS Filippo Falorni - Citi Steve Powers - Deutsche Bank Keith Devas - Jefferies Nik Modi - RBC Capital Markets Korinne Wolfmeyer - Piper Sandler Jeremy Fialko - HSBC Operator Hello, and welcome to the Kenvue Third Quarter 2024 Earnings Conference Call.
seekingalpha.com
- 1 week ago
Here's What Key Metrics Tell Us About Kenvue (KVUE) Q3 Earnings
Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
- 1 week ago
Kenvue (KVUE) Q3 Earnings Surpass Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago.
zacks.com
- 1 week ago
Kenvue misses quarterly sales estimates on sluggish skincare sales
Kenvue reported third-quarter sales marginally below Wall Street estimates on Thursday, hurt by weakness in its skin health and beauty unit housing the Neutrogena and Aveeno brands, amid pressure from activist hedge fund Starboard Value.
reuters.com
- 1 week ago
Kenvue Reports Third Quarter 2024 Results
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal third quarter ended September 29, 2024.
businesswire.com
- 1 week ago
Stay Ahead of the Game With Kenvue (KVUE) Q3 Earnings: Wall Street's Insights on Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Kenvue (KVUE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
zacks.com
- 1 week ago
This Big New Development Could Be Bullish for Kenvue Stock
Can tinkering around the edges actually make this stock more attractive?
fool.com
- 2 weeks ago
3 Dividend Stocks to Double Up on Right Now
While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio.
fool.com
- 2 weeks ago
Billionaire Ken Griffin Just Increased His Position in This Dividend Stock by 5,848%. Here's Why Now May Be a Great Time to Buy.
Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.
fool.com
- 3 weeks ago
Meet the 3.6%-Yielding Dividend King Stock That's Up 25% in 3 Months
An activist investor is taking a stake in Kenvue stock.
fool.com
- 3 weeks ago
How activist Starboard may help boost value in Kenvue's skin and beauty business
Starboard Value and Kenvue seem to be aligned, and the conditions might be right for value creation.
cnbc.com
- 3 weeks ago
8. Profile Summary
Kenvue Inc. KVUE
COUNTRY
US
INDUSTRY
Household & Personal Products
MARKET CAP
$ 45.7 B
Dividend Yield
0.89%
Description
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
Contact
199 Grandview Road, Skillman, NJ, 08558
https://www.kenvue.com
IPO Date
May 4, 2023
Employees
22000
Officers
Mr. Carlton Lawson
Group President of EMEA & Latin America
Ms. Ellie Bing Xie
Group President of Asia Pacific
Ms. Tina Romani
Head of Investor Relations
Mr. Matthew Orlando
General Counsel
Mr. Paul Ruh
Chief Financial Officer
Ms. Heather R. Howlett
Chief Accounting Officer
Mr. Bernardo Tavares
Chief Data & Technology Officer
Mr. Thibaut Mongon
Chief Executive Officer & Director
Dr. Caroline Tillett Ph.D.
Chief Scientific Officer
Ms. Meredith Stevens
Chief Operations Officer